DE2853453A1 - Mittel zur therapie von immunkomplexerkrankungen - Google Patents

Mittel zur therapie von immunkomplexerkrankungen

Info

Publication number
DE2853453A1
DE2853453A1 DE19782853453 DE2853453A DE2853453A1 DE 2853453 A1 DE2853453 A1 DE 2853453A1 DE 19782853453 DE19782853453 DE 19782853453 DE 2853453 A DE2853453 A DE 2853453A DE 2853453 A1 DE2853453 A1 DE 2853453A1
Authority
DE
Germany
Prior art keywords
antibody
immune complex
immune
therapy
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19782853453
Other languages
German (de)
English (en)
Other versions
DE2853453C2 (enExample
Inventor
Hans-Harald Dr Sedlacek
Friedrich Robert Dr Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DE19782853453 priority Critical patent/DE2853453A1/de
Priority to EP79104819A priority patent/EP0012305B1/de
Priority to DE7979104819T priority patent/DE2964386D1/de
Priority to AT79104819T priority patent/ATE2049T1/de
Priority to CA000341535A priority patent/CA1135185A/en
Priority to IL58906A priority patent/IL58906A/xx
Priority to NO794019A priority patent/NO794019L/no
Priority to US06/101,645 priority patent/US4479934A/en
Priority to JP15986479A priority patent/JPS5581817A/ja
Publication of DE2853453A1 publication Critical patent/DE2853453A1/de
Application granted granted Critical
Publication of DE2853453C2 publication Critical patent/DE2853453C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE19782853453 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen Granted DE2853453A1 (de)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19782853453 DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen
DE7979104819T DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases
AT79104819T ATE2049T1 (de) 1978-12-11 1979-12-01 Mittel zur therapie von immunkomplexerkrankungen.
EP79104819A EP0012305B1 (de) 1978-12-11 1979-12-01 Mittel zur Therapie von Immunkomplexerkrankungen
CA000341535A CA1135185A (en) 1978-12-11 1979-12-10 Agent for the therapy of immunocomplex diseases
IL58906A IL58906A (en) 1978-12-11 1979-12-10 Agent for the therapy of immunocomplex diseases
NO794019A NO794019L (no) 1978-12-11 1979-12-10 Middel til terapi av immunkomplekssykdommer.
US06/101,645 US4479934A (en) 1978-12-11 1979-12-10 Method and agent for the therapy of immunocomplex diseases
JP15986479A JPS5581817A (en) 1978-12-11 1979-12-11 Therapeutic drug for immunity compounded disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19782853453 DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen

Publications (2)

Publication Number Publication Date
DE2853453A1 true DE2853453A1 (de) 1980-06-19
DE2853453C2 DE2853453C2 (enExample) 1987-11-19

Family

ID=6056859

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19782853453 Granted DE2853453A1 (de) 1978-12-11 1978-12-11 Mittel zur therapie von immunkomplexerkrankungen
DE7979104819T Expired DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE7979104819T Expired DE2964386D1 (en) 1978-12-11 1979-12-01 Therapeutic means for immune complex diseases

Country Status (8)

Country Link
US (1) US4479934A (enExample)
EP (1) EP0012305B1 (enExample)
JP (1) JPS5581817A (enExample)
AT (1) ATE2049T1 (enExample)
CA (1) CA1135185A (enExample)
DE (2) DE2853453A1 (enExample)
IL (1) IL58906A (enExample)
NO (1) NO794019L (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) * 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
JPH0643343B2 (ja) * 1984-12-28 1994-06-08 株式会社ミドリ十字 免疫調節剤
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5422258A (en) * 1987-12-31 1995-06-06 Tanox Biosystems, Inc. Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH392780A (de) * 1961-12-07 1965-05-31 Schweiz Rotes Kreuz Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
DE2522086A1 (de) * 1974-05-20 1975-12-11 Technicon Instr Analyse von biologischen fluiden
DE2533183C3 (de) * 1974-07-25 1980-03-20 Institut Merieux, Lyon, Rhone (Frankreich) Verfahren zum Herstellen gereinigter Immunglobuline
DE2658334C3 (de) * 1976-12-23 1987-05-07 Behringwerke Ag, 3550 Marburg Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH392780A (de) * 1961-12-07 1965-05-31 Schweiz Rotes Kreuz Verfahren zur Herstellung von intravenös anwendbaren Antikörperpräparaten humanen Ursprungs
US3466368A (en) * 1967-06-02 1969-09-09 Us Health Education & Welfare Cleavage of human gamma globulin by means of cyanogen bromide
DE2522086A1 (de) * 1974-05-20 1975-12-11 Technicon Instr Analyse von biologischen fluiden
DE2522087A1 (de) * 1974-05-20 1975-12-11 Technicon Instr Biologische analyse
DE2533183C3 (de) * 1974-07-25 1980-03-20 Institut Merieux, Lyon, Rhone (Frankreich) Verfahren zum Herstellen gereinigter Immunglobuline
DE2658334C3 (de) * 1976-12-23 1987-05-07 Behringwerke Ag, 3550 Marburg Verfahren zum Herstellen von Immunglobulinpräparationen mit verminderter Komplementaktivität und ein diese enthaltendes Arzneimittel

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C.A. 79, 30333j, 1973 *
C.A. 79, 30334k, 1973 *
C.A. 82, 84193u, 1975 *

Also Published As

Publication number Publication date
DE2964386D1 (en) 1983-01-27
EP0012305A1 (de) 1980-06-25
EP0012305B1 (de) 1982-12-22
JPS5581817A (en) 1980-06-20
US4479934A (en) 1984-10-30
DE2853453C2 (enExample) 1987-11-19
ATE2049T1 (de) 1983-01-15
NO794019L (no) 1980-06-12
CA1135185A (en) 1982-11-09
IL58906A (en) 1982-11-30
IL58906A0 (en) 1980-03-31

Similar Documents

Publication Publication Date Title
DE69223641T2 (de) Stabilisierte antikörper
DE3751214T2 (de) Monoklonale Antikörper gegen Immunglobulin G Fc-Rezeptoren auf humane mononukleare Phagozyten; bifunktionelle Antikörper; ziel-spezifische Effektorzellen; gezielte Makrophagen und Immunoassays.
DE69014474T2 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DE2936047C2 (enExample)
DE69132045T2 (de) Monoklonale Antikörper gegen menschlichen Tumornekrosefaktor alpha
DE3752129T2 (de) Verwendung eines gegen das 17-1A Antigen gerichteten monoklonalen Antikörpers zur Herstellung eines Arzneimittels für die Behandlung von einem Magen-Darm-Tumor
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE60217698T2 (de) Behandlung chronischer gelenkentzündung unter verwendung eines antikörpers gegen das cd3 antigenkomplex
DE69033181T2 (de) Iga-rezeptorspezifische monoklonale antikörper
DE2846412C2 (enExample)
DE2853453C2 (enExample)
DE3785967T2 (de) Monoklonale Antikörper gegen C5A und DES-ARG74-C5A, ihre Herstellung und ihre Verwendung.
Sulica et al. Inhibition of human natural killer cell activity by cytophilic immunoglobulin G.
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
DE3218312A1 (de) Monoklonale antikoerper, hybridoma-zellklone, verfahren zu ihrer herstellung und ihre verwendung zur erkennung von brustkrebs und maligner lymphogranulomatose
DE2541931A1 (de) Immunologische verbindungen
EP0340604A2 (de) Monoklonaler Antikörper und seine Verwendung
DE3875306T2 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
CH632091A5 (en) Process for the preparation of an antiserum directed against placenta-specific glycoprotein
CH639394A5 (de) Verfahren zur herstellung von immunglobulinpraeparationen mit verminderter komplementaktivitaet.
EP0091784B1 (en) Products for use in treating cancer
US4465670A (en) Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor
DE3250068C2 (enExample)
DE2533183C3 (de) Verfahren zum Herstellen gereinigter Immunglobuline
Plescia et al. Fractionation and immunological properties of a DNA-rich preparation from Brucella abortus.

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee